GlassScriptPhysician profile
Marina V Oks
NPI 1891790903
$32,933.94
in general payments reported to CMS, 2019-2025
51 companies · $4,291 in 2025
The $4,291 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,197 · 2020: $3,390 · 2021: $5,423 · 2022: $6,693 · 2023: $4,735 · 2024: $4,206 · 2025: $4,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,231.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,277.86 | 2021-2025 | |
| Amgen INC. | $5,245.52 | 2019-2025 | Repatha, Evenity, Repatha |
| Astrazeneca Pharmaceuticals LP | $4,677.28 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,465.67 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,268.14 | 2019-2025 | Xifaxan, Trulance |
| Novo Nordisk INC | $804.92 | 2020-2025 | Ozempic, Rybelsus |
| Allergan, INC. | $799.78 | 2019-2020 | |
| Axsome Therapeutics, INC. | $778.12 | 2023-2025 | Auvelity, Symbravo |
| Alkermes, INC. | $756.98 | 2020-2025 | Lybalvi |
| Genzyme Corporation | $755.70 | 2020-2024 | |
| Teva Pharmaceuticals USA, INC. | $749.25 | 2021-2023 | Austedo |
| Janssen Pharmaceuticals, INC | $715.70 | 2019-2021 | |
| Lilly USA, LLC | $625.60 | 2019-2025 | Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $525.82 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $512.27 | 2019-2024 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marina Oks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.